Stocks and Investing
Stocks and Investing
Mon, April 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $343 on, Apr 19th, 2021
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $351 to $343 on, Apr 19th, 2021.
Matthew has made no other calls on BIIB in the last 4 months.
There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $245 on, Monday, April 12th, 2021
- Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $268 on, Wednesday, February 17th, 2021
These are the ratings of the 3 analyists that currently disagree with Matthew
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $305 on, Thursday, February 4th, 2021
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $338 on, Thursday, February 4th, 2021
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $380 on, Thursday, February 4th, 2021
Contributing Sources